Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Celltrion files for approval of Keytruda biosimilar, joining domestic race

24 August 2026 · By · Wire by Fusion42

Published

24 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

South Korea

◆ Source

Read at m.ajupress.com →

◆ Verified

Fusion42 · 24 August 2026 · Fusion42 review

Celltrion applied for South Korean regulatory approval of CT-P51, a biosimilar version of Merck's Keytruda, joining a domestic race with Samsung Bioepis to capture market share as the original drug's patent expires. The company confirmed pharmacokinetic equivalence in trials and plans to seek approvals in the US, Europe, and Canada.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face a fiercely competitive market as South Korea fast-tracks biosimilar approvals for blockbuster cancer drugs. Move now to explore partnerships or accelerate development to secure early market access before rivals solidify dominance.

◆ Coverage

1 source · 24 Aug 2026

◆ Related on Wire

◆ Topics

Biotechbiosimilarsdrug-approvalsouth-koreaimmuno-oncologykeytruda